Yuri McKee, MD
Ophthalmology · Mesa, AZNPI 1154313989
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Lensar, Inc. at 44.2% of the total. Reporting peaked in 2019 at $57,057 and has fallen 93.6% since, to $3,675 in 2025. Among ophthalmology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $423.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lensar, Inc.$44K
- Carl Zeiss Meditec, Inc.$17K
- Haag-streit USA, Inc.$12K
- Ivantis, Inc$9K
- Rxsight Inc$6K
- Oculus, Inc.$2K
- plus $9K from 14 others
Across 3 payments — averaging $3000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ivantis, Inc$9K
- Rxsight Inc$500
What the payments were for
- Consulting fees$22,25022%
- Speaking & faculty fees$38,94939%
- Grants$7501%
- Travel & lodging$26,72527%
- Food & beverage$10,88411%
- Gifts$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lensar, Inc. | 7 | $44,082 |
| Carl Zeiss Meditec, Inc. | 11 | $17,068 |
| Haag-streit USA, Inc. | 15 | $11,989 |
| Ivantis, Inc | 31 | $9,408 |
| Rxsight Inc | 16 | $6,214 |
| Oculus, Inc. | 3 | $2,102 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $1,911 |
| Bausch & Lomb Americas Inc. | 20 | $1,649 |
| AbbVie(2 entities) | 33 | $1,419 |
| Alcon | 55 | $1,172 |
| Carl Zeiss Meditec Digital Innovations LLC | 6 | $1,049 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $535 |
| Glaukos Corporation | 3 | $418 |
| Carl Zeiss Meditec USA, Inc. | 3 | $304 |
| Sun Pharmaceutical Industries Inc. | 2 | $131 |
| Dompe US, Inc. | 1 | $95 |
| Ocular Therapeutix, Inc. | 1 | $37 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Novartis | 1 | $15 |
| Eyepoint US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENSAR LASER SYSTEM$44,082
- VERACITY SURGICAL$8,036
- ARTEVO 800$6,556
- FORUM$6,500
- RXSIGHT CONTACT LENS$5,645
- RXSIGHT INJECTOR CARTRIDGE$5,645
- RXSIGHT INJECTOR HANDPIECE$5,645
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$5,645
- LIGHT ADJUSTABLE LENS (LAL)$5,510
- Hydrus$5,445
- Hydrus Microstent$3,935
- IOLMaster$3,850
- CALLISTO eye$3,406
- miLOOP$3,300
- IOLMaster 700$2,600
- ENVISTA$1,500
- CLARUS$1,306
- Retina Workplace$1,200
- FORUM Glaucoma Workplace$1,200
- Humphrey Field Analyzer (HFA3)$1,200
How this compares
$99,630 in reported general payments places this provider in the 95th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 486 | $15,523 |
| MoxifloxacinMoxifloxacin Hcl | 427 | $7,418 |
| Loteprednol Etabonate | 22 | $5,655 |
| Ketorolac Tromethamine | 400 | $5,597 |
| Fluorometholone | 26 | $2,410 |
| Latanoprost | 159 | $2,216 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 100 | $1,890 |
| Brimonidine Tartrate | 14 | $1,047 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $1,911 | $5,65522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Mesa
- Warren HillMesa$1.1M
- Derek KunimotoMesa$138K
- Mark BarakatScottsdale$794K
- Anne ZakiSun City West$518K
- Pravin DugelPhoenix$176K
- Shamil PatelGlendale$116K
- Nishi ShahPhoenix$92K
- Lisa MihoraPeoria$91K
- George ReissGlendale$73K
- Wendy HuangGlendale$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.